Почетна › Рак на дојка › Висконсин › Madison
Клинички испитувања за Рак на дојка во Madison, WI
22 студии за Рак на дојка бараат учесници на локации во и околу Madison (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Се регрутираФаза 1/2
- University of Wisconsin Carbone Cancer Center, Madison
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
- William S Middleton VA Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Се регрутираФаза 2
- UW Health Carbone Cancer Center, Madison
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Се регрутираФаза 2
- University of Wisconsin, Madison
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Се регрутираФаза 1
- Wisconsin Institute for Medical Research, Madison
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Се регрутираФаза 3
- Circuit Clinical/SSM Health Dean Medical Group ( Site 0039), Madison
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Се регрутираФаза 3
- University of Wisconsin-Madison ( Site 0024), Madison
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Се регрутираФаза 3
- University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0040), Madison
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Се регрутира
- University of Wisconsin, Madison
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Се регрутираФаза 1
- University of Wisconsin - Carbone Cancer Center, Madison
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Се регрутираФаза 3
- University of Wisconsin Carbone Cancer Center- University Hospital, Madison
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Се регрутираФаза 1/2
- University of Wisconsin-Madison Carbone Cancer Center, Madison
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Се регрутираФаза 3
- University of Wisconsin Carbone Cancer Center- University Hospital, Madison
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Се регрутираФаза 2
- University of Wisconsin, Madison
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Се регрутираФаза 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Study of 18F-FFNP Breast PET/MRI
Се регрутираФаза 2
- UW Carbone Cancer Center, Madison
Biomarkers to Detect Endocrine Therapy Resistance
Се регрутираФаза 2
- UW Carbone Cancer Center, Madison
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
Се регрутираФаза 2
- University of Wisconsin Carbone Cancer Center, Madison
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Се регрутираФаза 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Се регрутираНабљудувачка студија
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Се регрутираФаза 4
- University of Wisconsin, Madison
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Се регрутираФаза 1
- UW Carbone Cancer Center, Madison
Испитувања за Рак на дојка во други градови
- New York City, NY134 студии
- Houston, TX126 студии
- Boston, MA111 студии
- Nashville, TN80 студии
- Los Angeles, CA72 студии
- Edison, NJ68 студии
- St. Louis, MO64 студии
- Durham, NC63 студии
- Queens, NY63 студии
- Chicago, IL58 студии
- Philadelphia, PA56 студии
- Dallas, TX55 студии
Други студии во Madison
- Рак на простата29 студии
- Колоректален карцином22 студии
- Метастатски карцином21 студија
- Рак на бели дробови со не-мали клетки16 студии
- Акутна миелоидна леукемија16 студии
- Меланом15 студии
- Рак (сите типови)14 студии
- Карцином на јајниците13 студии
- Рак на стомакот11 студии
- Рак на бели дробови10 студии
- Карцином на панкреасот10 студии
- Множен миелом9 студии
Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.